[1]
|
Dewey Jr., R.B. (2004) Management of motor complications in Parkinson’s disease. Neurology, 62, S3-S7.
doi:10.1212/WNL.62.6_suppl_4.S3
|
[2]
|
Hoehn, M.M. and Yahr, M.D. (1967) Parkinsonism: Onset, progression and mortality. Neurology, 17, 427-442.
doi:10.1212/WNL.17.5.427
|
[3]
|
Parkinson, N.J., Robin, C., Newton, J. R., Slater, J. and Waller, A.S. (2011) Molecular epidemiology of strangles outbreaks in the UK during 2010. Veterinary Record, 168, 666. doi:10.1136/vr.d1485
|
[4]
|
Wirdefeldt, K., Adami, H.O., Cole, P., Trichopoulos, D. and Mandel, J. (2011) Epidemiology and etiology of Parkinson’s disease: A review of the evidence. European Journal of Epidemiology, 26, S1-S58.
doi:10.1007/s10654-011-9581-6
|
[5]
|
Henchcliffe, C. and Beal, M.F. (2007) Pathogenesis: Oxidative stress, mitochodrial dysfunction, and excito-toxicity. In: Factor, S.A. and Weiner, W.J., Eds., Parkinson’s Disease Diagnosis & Clinical Management, 2nd Edition, Demos Medical Publishing, New York, 341-356.
|
[6]
|
Jankovic, J. and Stacy, M. (2007) Medical management of levodopaassociated motor complications in patients with Parkinson’s disease. CNS Drugs, 21, 677-692.
doi:10.2165/00023210-200721080-00005
|
[7]
|
Schwid, S.R., Shoulson, I., Stern, M., Oakes, D., Kieburtz, K., Fahn, S., et al. (2005) A randomized placebo-controlled trial of rasagiline in levodopatreated patients with Parkinson disease and motor fluctuations: The PRESTO study. Archives of Neurology, 62, 241-248.
doi:10.1001/archneur.62.2.241
|
[8]
|
Simuni, T., Hurtig, H., Adler, C.H., Rajput, A., Zesiewicz, T.A., Hauser, R.A., et al. (2007) Drugs. In: Factor, S.A. and Weiner, W.J., Eds., Parkinson’s Disease Diagnosis & Clinical Management, Demos Medical Publishing, New York, 471-571.
|
[9]
|
Smith, L.P. (2003) Steady the course of Parkinson’s disease. Nurs Manage, 34, 35-39.
doi:10.1097/00006247-200304000-00011
|
[10]
|
Solla, P., Cannas, A., Marrosu, F. and Marrosu, M.G. (2010) Therapeutic interventions and adjustments in the management of Parkinson disease: Role of combined carbidopa/levodopa/entacapone (Stalevo). Journal of Neu-ropsychiatric Disease and Treatment, 6, 483-490.
doi:10.2147/NDT.S5190
|
[11]
|
Tarrants, M.L., Denarie, M.F., Castelli-Haley, J., Millard, J. and Zhang, D. (2010) Drug therapies for Parkinson’s disease: A database analysis of patient compliance and persistence. American Journal of Geriatric Pharmaco-therapy, 8, 374-383.
doi:10.1016/j.amjopharm.2010.08.001
|
[12]
|
Gardian, G. and Vecsei, L. (2010) Medical treatment of Parkinson’s disease: Today and the future. International Journal of Clinical Pharmacology, Therapy, 48, 633-642.
|
[13]
|
Caslake, R., Macleod, A., Ives, N., Stowe, R. and Counsell, C. (2009) Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson’s disease. Cochrane Database of Systematic Reviews, 4, CD006661.
|
[14]
|
Stowe, R., Ives, N., Clarke, C. E., Deane, K., Wheatley, K., Gray, R., et al. (2010) Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database of Systematic Reviews, 7, CD007166.
|
[15]
|
Myllyla, V.V., Sotaniemi, K.A., Vuorinen, J.A. and Heinonen, E.H. (1993) Selegiline in de novo parkinsonian patients: The Finnish study. Movement Disorders, 8, S41- S44. doi:10.1002/mds.870080509
|
[16]
|
Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Archives of Neurology, 62, 241-248.
doi:10.1001/archneur.62.2.241
|
[17]
|
Sivertsen, B., Dupont, E., Mikkelsen, B., Mogensen, P., Rasmussen, C., Boesen, F., et al. (1989) Selegiline and levodopa in early or moderately advanced Parkinson’s disease: A double-blind controlled short-and long-term study. Acta Neurologica Scandinavica, Supplementum, 126, 147-152. doi:10.1111/j.1600-0404.1989.tb01794.x
|
[18]
|
Boyson, S.J. (1991) Psychiatric effects of selegiline. Archives of Neurology, 48, 902.
doi:10.1001/archneur.1991.00530210028017
|
[19]
|
Kurlan, R and Dimitsopulos, T. (1992) Selegiline and manic behavior in Parkinson’s disease. Archives of Neurology, 49, 1231.
doi:10.1001/archneur.1992.00530360029012
|
[20]
|
Talati, R., Reinhart, K., Baker, W., White, C.M. and Coleman, C.I. (2009) Pharmacologic treatment of advanced Parkinson’s disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism & Related Disorders, 15, 500-505.
doi:10.1016/j.parkreldis.2008.12.007
|
[21]
|
Kurth, M.C. and Adler, C.H. (1998) COMT inhibition: A new treatment strategy for Parkinson’s disease. Neurology, 50, S3-S14. doi:10.1212/WNL.50.5_Suppl_5.S3
|
[22]
|
Adler, C.H., Singer, C., O’Brien, C., Hauser, R.A., Lew, M.F., Marek, K.L., et al. (1998) Randomized, placebo- controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tol-capone Fluctuator Study Group III. Archives of Neurology, 55, 1089-1095. doi:10.1001/archneur.55.8.1089
|
[23]
|
Brooks, D.J., Leinonen, M., Kuoppamaki, M. and Nissinen, H. (2008) Five-year efficacy and safety of levodopa/ DDCI and entacapone in patients with Parkinson’s disease. Journal of Neural Transmission, 115, 843-849.
doi:10.1007/s00702-008-0025-8
|
[24]
|
Kurth, M.C., Adler, C.H., Saint-Hilaire, M., Singer, C., Waters, C., LeWitt, P., et al. (1997) Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: A multicenter, double-blind, randomized, place-bo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology, 48, 81-87. doi:10.1212/WNL.48.1.81
|
[25]
|
Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study Group. Annals of Neurology, 42, 747-755.
|
[26]
|
Rajput, A.H., Martin, W., Saint-Hilaire, M.H., Dorflinger, E. and Pedder, S. (1997) Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: A double-blind, placebo-controlled, multicenter trial. Neurology, 49, 1066-1071.
doi:10.1212/WNL.49.4.1066
|
[27]
|
Rascol, O., Brooks, D.J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., et al. (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet, 365, 947-954.
doi:10.1016/S0140-6736(05)71083-7
|
[28]
|
Hemming, J.P., Gruber-Baldini, A.L., Anderson, K.E., Fishman, P.S., Reich, S.G., Weiner, W.J., et al. (2011) Racial and socioeconomic disparities in parkinsonism. Archives of Neurology, 68, 498-503.
doi:10.1001/archneurol.2010.326
|
[29]
|
Van Den Eeden, S.K., Tanner, C.M., Bernstein, A.L., Fross, R.D., Leimpeter, A., Bloch, D.A., et al. (2003) Incidence of Parkinson’s disease: Variation by age, gender, and race/ethnicity. American Journal of Epidemiology, 157, 1015-1022. doi:10.1093/aje/kwg068
|
[30]
|
Marder, K.S. and Jacobs, D.M. (2007) Dementia. In: Factor, S.A. and Weiner, W.J., Eds., Parkinson’s Disease Diagnosis & Clinical Management, Demos Medical Publishing, New York.
|
[31]
|
Aarsland, D., Andersen, K., Larsen, J.P., Lolk, A., Nielsen, H.and Kragh-Sorensen, P. (2001) Risk of dementia in Parkinson’s disease: A community-based, prospective study. Neurology, 56, 730-736.
doi:10.1212/WNL.56.6.730
|
[32]
|
Hughes, T.A., Ross, H.F., Musa, S., Bhattacherjee, S., Nathan, R.N., Mindham, R.H., et al. (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology, 54, 1596-1602.
|
[33]
|
Gunzler, S.A. and Nutt, J.G. (2007) Motor fluctuations and dyskinesia. In: Factor, S.A. and Weiner, W.J., Eds., Parkinson’s Disease Diagnosis & Clinical Management, Demos Medical Publishing, New York.
|